Quick Answer
Tarsus Pharmaceuticals, Inc. reported Total Revenue of $451.36 million for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $451.36M +146.7% |
$182.95M +948.6% |
$17.45M -32.4% |
$25.82M -54.7% |
$57.03M | $0.00 |
| Net Income | -$66.42M +42.5% |
-$115.55M +15.0% |
-$135.89M -118.9% |
-$62.09M -349.1% |
-$13.83M +48.4% |
-$26.81M -474.1% |
| Diluted EPS | -$1.59 +48.2% |
-$3.07 +33.5% |
-$4.62 -83.3% |
-$2.52 -276.1% |
-$0.67 +84.5% |
-$4.32 |
| Total Assets | $562.16M +49.1% |
$376.99M +42.0% |
$265.49M +16.5% |
$227.86M +27.4% |
$178.91M +4.0% |
$171.97M +194.9% |
| Cash and Equivalents | — | — | $224.95M +213.9% |
$71.66M -58.2% |
$171.33M +1.9% |
$168.13M +190.1% |
| Long-Term Debt | $72.44M +0.8% |
$71.84M +140.9% |
$29.82M +53.4% |
$19.43M | $0.00 | — |
| Stockholders Equity | $343.43M +53.0% |
$224.53M +14.0% |
$196.99M +2.1% |
$192.90M +15.7% |
$166.73M +0.5% |
$165.98M +2864.0% |
| R&D Expense | $64.32M +20.5% |
$53.39M +6.1% |
$50.31M +18.0% |
$42.62M +2.2% |
$41.71M +121.6% |
$18.83M +495.4% |
| Operating Income | -$70.97M +41.1% |
-$120.57M +15.8% |
-$143.16M -128.3% |
-$62.71M -415.9% |
-$12.16M +55.0% |
-$27.00M -528.2% |
| Shares Outstanding | 42.55M +11.0% |
38.35M +12.1% |
34.21M +28.1% |
26.70M +29.0% |
20.70M +1.8% |
20.32M +667.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $118.70M | +146.7% | +15.6% |
| Net Income | September 30, 2025 | -$12.59M | +46.3% | +38.1% |
| Diluted EPS | September 30, 2025 | -$0.30 | +50.8% | +37.5% |
| Total Assets | September 30, 2025 | $534.56M | +42.1% | +8.0% |
| Cash and Equivalents | June 30, 2022 | $245.36M | +38.8% | +40.2% |
| Long-Term Debt | September 30, 2025 | $72.28M | +0.8% | +0.2% |
| Stockholders Equity | September 30, 2025 | $335.08M | +41.1% | +0.7% |
| R&D Expense | September 30, 2025 | $16.28M | +34.3% | +4.4% |
| Operating Income | September 30, 2025 | -$14.53M | +42.3% | +34.5% |
| Shares Outstanding | September 30, 2025 | 42.45M | +11.1% | +0.6% |
- Tarsus Pharmaceuticals, Inc. reported Total Revenue of $451.36 million for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +146.7% in Total Revenue compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported Net Income of -$66.42 million for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +42.5% in Net Income compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported Diluted EPS of $1.59 per share (loss) for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +48.2% in Diluted EPS compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported Total Assets of $562.16 million for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +49.1% in Total Assets compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported Cash and Equivalents of $224.95 million for fiscal year 2023.
- Tarsus Pharmaceuticals, Inc. showed an increase of +213.9% in Cash and Equivalents compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported Long-Term Debt of $72.44 million for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +0.8% in Long-Term Debt compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported Stockholders Equity of $343.43 million for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +53.0% in Stockholders Equity compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported R&D Expense of $64.32 million for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +20.5% in R&D Expense compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported Operating Income of -$70.97 million for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +41.1% in Operating Income compared to the prior fiscal year.
- Tarsus Pharmaceuticals, Inc. reported Shares Outstanding of 42.55 million shares for fiscal year 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +11.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: